Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $11 from $18 and keeps a Neutral rating on the shares after the company announced a voluntary and temporary pause in Elevidys shipments, effective at the close of business on July 22, 2025. This decision is intended to provide the company with the necessary time to address any information requests and facilitate the completion of the Elevidys safety labeling supplement process in collaboration with the FDA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Stock (SRPT) Could Crash to $0, Warns Wainwright Analyst
- Sarepta Therapeutics’ Shipment Pause of Elevidys: Strategic Move Amidst Regulatory Concerns
- Sarepta downgraded to Equal Weight from Overweight at Barclays
- Sarepta announces voluntary pause of Elevidys shipments in the U.S.
- Verizon reports Q2 beat, Block to join S&P 500: Morning Buzz